Gilteritinib in Isolated Breast Relapse of FLT3 Positive Acute Myeloid Leukemia: A Case Report and Review of Literature

Arrigo G. · D’Ardìa S. · Audisio E. · Cerrano M. · Freilone R. · Giai V. · Secreto C. · Urbino I. · Frairia C.

Author affiliations

Division of Hematology, Department of Oncology, AOU Città della Salute e della Scienza, Turin, Italy

Log in to MyKarger to check if you already have access to this content.

Buy FullText & PDF Unlimited re-access via MyKarger Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent/Cloud Rent for 48h to view Buy Cloud Access for unlimited viewing via different devices Synchronizing in the ReadCube Cloud Printing and saving restrictions apply Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe Access to all articles of the subscribed year(s) guaranteed for 5 years Unlimited re-access via Subscriber Login or MyKarger Unrestricted printing, no saving restrictions for personal use read more

Subcription rates

Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

Received: March 01, 2022
Accepted: May 01, 2022
Published online: May 17, 2022

Number of Print Pages: 5
Number of Figures: 2
Number of Tables: 0

ISSN: 0001-5792 (Print)
eISSN: 1421-9662 (Online)

For additional information: https://www.karger.com/AHA

Abstract

Extramedullary relapse of acute myeloid leukemia (AML) is not a rare event, and the FMS-like tyrosine kinase 3 (FLT3) mutation is a well-known risk factor. Gilteritinib is approved for relapsed/refractory FLT3+ AML, but its efficacy in extramedullary relapse is still undefined. Here, we present the case of a 69-year-old woman with therapy-related nucleophosmin-1 and FLT3-internal tandem duplication (FLT3-ITD) positive AML treated with induction and consolidation with CPX-351 (liposomal daunorubicin plus cytarabine) followed by off-label azacitidine maintenance who obtained a complete remission (CR) with persistent measurable residual disease. After 19 months of CR, she experienced an isolated breast relapse of FLT3-ITD+ AML. She was started on single-agent gilteritinib, resulting in a rapid and persistent complete regression of the breast nodule. Targeted therapy with gilteritinib for relapsed/refractory FLT3-ITD+ AML can be effective in isolated extramedullary relapse.

© 2022 S. Karger AG, Basel

References Pollyea DA, Bixby D, Perl A, Bhatt VR, Altman JK, Appelbaum FR, et al. Acute myeloid leukemia, version 2.2021 featured updates to the NCCN guidelines. J Natl Compr Cancer Netw. 2021;19(1):16–27. Welch JS, Ley TJ, Link DC, Miller CA, Larson DE, Koboldt DC, et al. The origin and evolution of mutations in acute myeloid leukemia. Cell. 2013;150(2):264–78. Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209–21. Perl AE, Martinelli G, Cortes JE, Neubauer A, Berman E, Paolini S, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3 -mutated AML. N Engl J Med. 2019;381(18):1728–40. Patel JP, Gönen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2013;366(12):1079–89. Cerrano M, Duchmann M, Kim R, Vasseur L, Hirsch P, Thomas X, et al. Clonal dominance is an adverse prognostic factor in acute myeloid leukemia treated with intensive chemotherapy. Leukemia. 2021;35(3):712–23. Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–47. Solh M, Solomon S, Morris L, Holland K, Bashey A. Extramedullary acute myelogenous leukemia. Blood Rev. 2016;30(5):333–9. Yilmaz AF, Saydam G, Sahin F, Baran Y. Granulocytic sarcoma: a systematic review. Am J Blood Res. 2013;3(4):265–70. Bakst RL, Tallman MS, Douer D, Yahalom J. How I treat extramedullary acute myeloid leukemia. Blood. 2011;118(14):3785–93. Bourlon C, Lipton JH, Deotare U, Gupta V, Kim DD, Kuruvilla J, et al. Extramedullary disease at diagnosis of AML does not influence outcome of patients undergoing allogeneic hematopoietic cell transplant in CR1. Eur J Haematol. 2017;99(3):234–9. Kida M, Kuroda Y, Kido M, Chishaki R, Kuraoka K, Ito T. Successful treatment with gilteritinib for isolated extramedullary relapse of acute myeloid leukemia with FLT3-ITD mutation after allogeneic stem cell transplantation. Int J Hematol. 2020;112(2):243–8. Perrone S, Ortu La Barbera E, Viola F, Cipollone E, Scerpa MC, Siniscalchi R, et al. A relapsing meningeal acute myeloid leukaemia FLT3-ITD+ responding to gilteritinib. Chemotherapy. 2021;66(4):134–8. Kumode T, Rai S, Tanaka H, Espinoza JL, Kakutani H, Watatani Y, et al. Targeted therapy for medullary and extramedullary relapse of FLT3-ITD acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation. Leuk Res Rep. 2020;14:100219. Kim RS, Yaghy A, Wilde LR, Shields CL. An iridociliochoroidal myeloid sarcoma associated with relapsed acute myeloid leukemia with FLT3-ITD mutation, treated with gilteritinib, an FLT3 inhibitor. JAMA Ophthalmol. 2020 Apr 1;138(4):418–9. McMahon CM, Canaani J, Rea B, Sargent RL, Qualtieri JN, Watt CD, et al. Gilteritinib induces differentiation in relapsed and refractory FLT3-mutated acute myeloid leukemia. Blood Adv. 2019;3(10):1581–5. Krönke J, Bullinger L, Teleanu V, Tschürtz F, Gaidzik VI, Kühn MWM, et al. Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia. Blood. 2013 Jul 4;122(1):100–8. Burns A. Observations of surgical anatomy, head and neck. Edinburgh: Thomas Royce; 1811. p. 364–6. King A. A case of chloroma. Monthly J Med. 1853;17:97. Cui Y, Zhou JL, Wu JH, Zhang JZ. Synchronous granulocytic sarcoma of the breast and spine: a case report and review of the literature. Chin Med J. 2008;121(18):1854–6. Dock G. Chloroma and its relation to leukemia. Am J Med Sci. 1893;106(2):153–7. Gomaa W, Ghanim A, Emam E, Bayoumi K, Ghanim A. Primary myeloid sarcoma of the breast: a case report and review of literature. J Microsc Ultrastruct. 2018;6(4):212–4. Yui J, Mudireddy M, Patnaik MM, Gangat N, Al-Kali A, Elliott M, et al. Myeloid sarcoma: the Mayo Clinic experience of ninety six case series. Blood. 2016 Dec 2;128(22):2798. Sharma A, Das AK, Pal S, Bhattacharyya S. Fine-needle aspiration cytology of granulocytic sarcoma presenting as a breast lump: report of a rare case with a comprehensive literature search. J Lab Physicians. 2018;10:113–5. Jelić-Puškarić B, Ostojić-Kolonić S, Planinc-Peraica A, Obad-Kovačević D, Kardum-Skelin I, Jakšić B. Myeloid sarcoma involving the breast. Coll Antropol. 2010;34(2):641–4. Zhang XH, Zhang R, Li Y. Granulocytic sarcoma of abdomen in acute myeloid leukemia patient with inv(16) and t(6;17) abnormal chromosome: case report and review of literature. Leuk Res. 2010;34(7):958–61. Ganzel C, Lee JW, Fernandez HF, Paietta EM, Luger SM, Lazarus HM, et al. CNS involvement in AML at diagnosis is rare and does not affect response or survival: data from 11 ECOG-ACRIN trials. Blood Adv. 2021;5(22):4560–8. Heuser M, Ofran Y, Boissel N, Brunet Mauri S, Craddock C, Janssen J, et al. Acute myeloid leukaemia in adult patients: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(6):697–712. Cunningham I, Kohno B. 18FDG-PET/CT: 21st century approach to leukemic tumors in 124 cases. Am J Hematol. 2016;91(4):379–84. Grunwald MR, Levis MJ. FLT3 tyrosine kinase inhibition as a paradigm for targeted drug development in acute myeloid leukemia. Semin Hematol. 2015;52(3):193–9. Urbino I, Secreto C, Olivi M, Apolito V, D’ardia S, Frairia C, et al. Evolving therapeutic approaches for older patients with acute myeloid leukemia in 2021. Cancers. 2021;13(20):5075. Article / Publication Details

Received: March 01, 2022
Accepted: May 01, 2022
Published online: May 17, 2022

Number of Print Pages: 5
Number of Figures: 2
Number of Tables: 0

ISSN: 0001-5792 (Print)
eISSN: 1421-9662 (Online)

For additional information: https://www.karger.com/AHA

Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

留言 (0)

沒有登入
gif